Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.» Read More
On Tuesday, Cramer highlighted the action—and potential M&A activity—in the fight to cure hepatitis C.
In the last two days Sanofi has hired a proxy solicitor and its bankers have become more aggressive in seeking out the opinions of Genzyme shareholders about what price they would accept in a hostile offer.
So far this year, the performance of the biotechnology index has been strong. So is there room for more growth in the sector? Mark Schoenebaum, managing director and senior research analyst at Deutsche Bank Securities shared his stock picks.
We are market trend followers and we’re 100 percent in cash at the moment because the trend has turned negative, said Graham Bibby, CEO and CIO of Richmond Asset Management. He shared his investment strategy.
Bristol-Myers Squibb headquarters have moved from New York City to Portland, Oregon and Genzyme’s from Cambridge, Massachusetts to Seattle. Not for real, but in the movie “Extraordinary Measures” that opens today. I got to see it last night at the New York premiere.
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
I went to the beleaguered Genzyme manufacturing plant in Allston, MA yesterday to get briefed on what exactly happened/is happening there for background ahead of my interview today with the CEO.
Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
With money rotating out of tech and energy are these two scorching sectors starting to cool down?
The audience tests Cramer’s 30 years of Wall Street experience with questions about Berkshire Hathaway’s legendary leader, 401(k)s versus Roth IRAs, alternative energy and more.
The market has taken down plenty of firms over the past 18 months. But did they all deserve it?
Those who forget the past are doomed NOT to repeat it.
Cougar Biotech has a drug in its pipeline that could offer big help to patients with this disease.
Why wouldn’t they? They’ve made a lot of money during this downturn. But that might be changing now.
Speculation offers the chance for big returns, which is just the thing investors need right now.
This company has heart, Cramer says. Find out how BSX fought its way off the operating table.
It’s easy to like a company that, even in this environment, is focused on taking share.
CEO David Pyott tells investors to think of more than just Botox when his company is mentioned.
The Democrats aren’t the only enemy of Big Pharma. The Fourth Estate has its own crusade against the group.